Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schultz, Thomas
eMOFEE, NCT04869384: Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma	Recruiting	4	166	Europe	Reminders and feedback to improve adherence, No reminders and feedback to improve adherence	Orion Corporation, Orion Pharma	Asthma	04/23	04/23
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Nov 2023 - Dec 2023 : Acceptance of regulatory submission in China for chronic rhinosinusitis with nasal polyps	Recruiting	3	1700	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	09/25	09/25
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy	Recruiting	2	464	Europe, RoW	Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo	Chiesi Farmaceutici S.p.A.	Uncontrolled Asthma	12/25	12/25